Fig. 2From: Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugsROC curves indicating the predictive value of calprotectin and clinical predictors for disease flare within 12 months of tapering in the IMPROVED (a, c) and RETRO (b, d) studies. a, b Circulating calprotectin levels (ng/mL) at the moment of DMARD tapering/stopping. c, d Comparison of models including clinical predictors only (dashed line) and clinical predictors in combination with circulating calprotectin levels (solid line). The p value is based on the test for equality of AUCsBack to article page